Clinical Trials Browser

Phase 1 × Lymphoma, Non-Hodgkin × Alemtuzumab × Clear all

NCT05557903 2022-09-28

Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL

Phase 1 Unknown

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, T-Cell

NCT03132584 2019-01-14

Cyclophosphamide and Alemtuzumab In Lymphoma

Phase 1 Terminated

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT00323323 2017-01-20

CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas

Phase 1 Completed

Lymphoma, Non-Hodgkin

NCT00161590 2008-10-22

Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma

Phase 1 Completed

Lymphoma, Non-Hodgkin, Lymphoma, T-Cell